Ember LifeSciences wins Alfresa backing for Japan cold chain push
US cold chain technology firm Ember LifeSciences has struck a capital and business alliance with Alfresa, Japan's largest pharmaceutical wholesaler. The deal hands the Los Angeles company a strategic investor, an exclusive distributor and a route into one of the world's biggest and most demanding drug markets.
Alfresa is a subsidiary of Tokyo-listed Alfresa Holdings (TSE: 2784), which reported revenue of 3.1 trillion yen ($20 billion) for the year to March 2026. It will invest in Ember's series A preferred stock and take exclusive rights to sell Ember's healthcare products across Japan's health sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze